Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review

Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-03, Vol.32 (15), p.1645-1653
Hauptverfasser:	Kawai, Kosuke, Preaud, Emmanuelle, Baron-Papillon, Florence, Largeron, Nathalie, Acosta, Camilo J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Allergy and Immunology Applied microbiology Biological and medical sciences Cost-Benefit Analysis Cost-effectiveness Discount rates Economic impact Europe Fundamental and applied biological sciences. Psychology herpes zoster Herpes Zoster - prevention & control Herpes Zoster Vaccine - economics Herpes Zoster Vaccine - therapeutic use Human viral diseases Humans Immunization Infectious diseases Medical sciences Microbiology Middle Aged Neuralgia, Postherpetic - prevention & control North America postherpetic neuralgia Quality of life Quality-Adjusted Life Years Sensitivity analysis shingles Studies vaccination Vaccination - economics vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in this review show that vaccination against HZ is likely to be cost-effective.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.01.058